Novartis AG
NVSNYSEHealthcare● Active
$146.42
$-2.74(-1.84%)
Market Cap$279.4B
P/E Ratio—
52W High$170.46
52W Low$112.34
Novartis AG（NVS）· 资产负债表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · NVS · 截至 2026-06-10
财务报表
Total Assets · Total Liabilities · Equity
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & ST Investments | $11.59B | $13.35B | $13.96B | $18.61B | $28.11B |
| Net Receivables | $10.93B | $8.21B | $9.38B | $9.89B | $9.62B |
| Inventory | $6.27B | $5.72B | $5.91B | $7.17B | $6.67B |
| Total Current Assets | $30.46B | $29.70B | $30.48B | $36.91B | $45.72B |
| PP&E Net | $12.35B | $10.87B | $10.92B | $12.20B | $13.11B |
| Goodwill | $25.57B | $24.76B | $23.34B | $29.30B | $29.59B |
| Intangible Assets | $29.41B | $26.91B | $26.88B | $31.64B | $34.18B |
| Total Assets | $115.57B | $102.25B | $99.94B | $117.45B | $131.79B |
| Liabilities | |||||
| Short-Term Debt | $5.78B | $8.09B | $6.08B | $5.88B | $6.23B |
| Accounts Payable | $4.46B | $4.57B | $4.93B | $5.15B | $5.55B |
| Total Current Liabilities | $27.28B | $28.69B | $26.39B | $28.66B | $30.21B |
| Long-Term Debt | $29.59B | $21.37B | $18.44B | $20.24B | $22.90B |
| Total Liabilities | $69.02B | $58.12B | $53.20B | $58.03B | $63.97B |
| Stockholders Equity | |||||
| Retained Earnings | $44.72B | $46.56B | $49.65B | $63.54B | $70.99B |
| Total Stockholders Equity | $46.13B | $44.05B | $46.67B | $59.34B | $67.66B |
| Total Liab & Equity(computed) | $115.15B | $102.17B | $99.86B | $117.37B | $131.63B |
| Debt Summary | |||||
| Total Debt | $37.03B | $31.26B | $26.35B | $27.91B | $31.02B |
| Net Debt | $25.60B | $19.80B | $12.96B | $20.39B | $18.62B |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Novartis AG
关于Novartis AG（NVS）资产负债表
Novartis AG总资产$115.57B，现金及短期投资$11.59B，总负债$69.02B，总债务$37.03B，股东权益$46.13B。
常见问题
NVS · 4 问Novartis AG总债务$37.03B，净债务$25.60B。
NVS total debtnet debtdebt to equity
· Source: FMP /stable/balance-sheet-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10